UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): February 12, 2013

 


 

ZIOPHARM Oncology, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-33038   84-1475672

(State or Other Jurisdiction

of Incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

1180 Avenue of the Americas
20th Floor
New York, NY
  10036
(Address of Principal Executive Offices)   (Zip Code)

 

(646) 214-0700

(Registrant’s telephone number, including area code)

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 


 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

 

 
 

 

 

Item 8.01 Other Events

 

ZIOPHARM Oncology, Inc., or the Company, announced today that the Phase 3 trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma(PICASSO 3) has reached its target number of progression-free survival (PFS) events, and that top line data from PICASSO 3 will be announced by the Company during the last week of March 2013.

 

A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

  

Item 9.01 Financial Statements and Exhibits
       
    (d) Exhibits    
       
  Exhibit No.   Description
       
  99.1   Press release of the Company dated February 12, 2013

 

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  ZIOPHARM Oncology, Inc.
   
   
  By: /s/ Jason A. Amello
Date: February 12, 2013   Name: Jason A. Amello
    Title: Executive Vice President and Chief Financial Officer

 

 

3
 

 

INDEX OF EXHIBITS

 

Exhibit No.   Description
     
99.1   Press release of the Company dated February 12, 2013
     
     
     
     

 

 

4